Thinking up tomorrow's medicine
On May 28th, at the Ecole des Mines de Nantes, the fourth Digital & Health day took place. It was organized by Images & Réseaux and Atlanpole Biotherapies competitive clusters. The objective of this cycle of theme days is to develop closer links between professionals involved in health and digital sectors.
[Press Release] Advanced Accelerator Applications S.A., an international specialist in Molecular Nuclear Medicine (MNM) and member of Atlanpole Biotherapies, announce s that it has entered into a distribution agreement for Lutathera in Japan with FUJIFILM RI Pharma, Co., LTD (“FRI”), a leading in - country distributor of nuclear medicine and diagnostic imaging products. Lutathera is currently in a pivotal Phase III trial, both in the US and EU, with results expected in Q3.
[Press Release] BIOMATLANTE (Vigneux de Bretagne ), a medical devices company specialized in bone regeneration and member of Atlanpole Biotherapies, today announced the CE regulatory approval of OSTEOTWIN™ Affix Sheath 1 , combining a polymer with its MBCP™ core technology, to significantly enhance fixation strength and graft protection. This product is the result of a development partnership between BIOMATLANTE and AMPLITUDE (Valence ).
Many types of diseases, whether of genetic origin or not, present a severe dysfunction or generalized dysfunctions of the liver, which can only be treated by liver transplant. The transplantation of hepatocytes, the functional cells of the liver, is a promising alternative to liver transplant but faces a shortage in human hepatocytes to be transplanted. One of the objectives of the CESTI IHU, is to develop innovative therapies: its tender “support for innovative projects” has selected the StemHepTher project coordinated by Dr. Tuan Huy Nguyen (Inserm UMR 1064 / ITUN).
The only rigorous mapping of French biotech, which is free and has been updated annually for 13 years, the Biotech finances BioMap allows international investors and industrialists to locate, at a glance, the lifeblood of French bioindustry. This document, translated into English, is very widely distributed in international economic and financial spheres.
From June 8 - 12, 14 PhD students in biotechnology and nanomedicine from 8 different nationalities participated in the second edition of the BioBusiness Week that took place at the Angers Technopole. They benefited from the experience of European professionals ready to share their know-how and willing to coach students on different issues such as market studies, intellectual property, fundraising…
In 2003, Caroline Le Guiner completed her PhD in Sciences, specializing in genetic and molecular biology particularly in the study of the regulation of alternative splicing. During this work, she was attached to the Cancer Research Institute in Nantes. After years of basic research on the cellular regulation mechanisms, she aspires to use the results of her work in a more concrete way. Thus, her great interest in medicine and patients led her towards applied research. Philippe Moullier, a medical doctor by training, who is also a researcher at INSERM and the founder of Nantes Gene Therapy Laboratory, accepted her in for her post doctorate work. 11 years later, she is still working in the same lab, where she is leading a gene therapy research program, whose goal is to develop drugs to treat a rare disease, Duchenne muscular dystrophy. A first clinical trial is expected to begin within a few months.
Research, Cancer, Ethics Bioinformatics, Plant science Mitochondrial medicine... Share your knowledge with international researchers and students from different countries and cultures.
Meet our companies there :
The CMSB 2015 conference will be held in Nantes from Sept. 16th to Sept. 18th. The conference brings together computer scientists, biologists, mathematicians, engineers and physicists interested in a system-level understanding of biological processes.
The Atlanpole Biotherapies competitive cluster combines the expertise of laboratories, companies and technical departments for a public-private offer of services, comprehensive, relevant and competitive, in the value chain of bio-medicine from target discovery to clinical evaluation.
Our ambition is to become a reference center on an international scale for the development of diagnostic and therapeutic solutions in the field of biotherapies.
Atlanpole Biotherapies is a competitive cluster certified by the Ministry of Industry (July 2005).